|
14 Companies |
|
16 Products |
|
16 Products |
|
24 Mechanisms of Action |
|
3 Trials |
|
179 News |
|
| 1234» |
- | NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial withdrawal, IO biomarker, Virus specific T cells: VISIT: Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - May 9, 2019
P1/2, N=0, Withdrawn, Sponsor: St. Anna Kinderkrebsforschung
N=30 --> 0 | Trial completion date: Mar 2020 --> Apr 2019 | Recruiting --> Withdrawn
- ||| NN1213 / Novo Nordisk
Trial completion, Diagnostic assay: T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays (clinicaltrials.gov) - Apr 25, 2019
P=N/A, N=600, Completed, Sponsor: Oxford Immunotec
N=30 --> 0 | Trial completion date: Mar 2020 --> Apr 2019 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China (clinicaltrials.gov) - Apr 23, 2019
P=N/A, N=8855, Completed, Sponsor: Jun Zhang
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=5000 --> 8855
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial completion date: Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant (clinicaltrials.gov) - Feb 22, 2019
P4, N=120, Completed, Sponsor: Ronaldo de Matos Esmeraldo, MD
Active, not recruiting --> Completed | N=5000 --> 8855 Active, not recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017
- | Trial completion, Post-transplantation: EVERCMV: Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (clinicaltrials.gov) - Nov 14, 2018
P4, N=186, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=60, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2019 --> May 2018
- | NN1213 / Novo Nordisk
Trial completion: Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant (clinicaltrials.gov) - Oct 3, 2018
P4, N=160, Completed, Sponsor: ORIOL BESTARD
Recruiting --> Completed | Trial completion date: Mar 2019 --> May 2018 Active, not recruiting --> Completed
- | Trial suspension, Trial primary completion date, IO biomarker, Gene therapy: CMV_TCR-001: Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT (clinicaltrials.gov) - Sep 12, 2018
P1, N=10, Suspended, Sponsor: University College, London
Active, not recruiting --> Completed Recruiting --> Suspended | Trial primary completion date: Apr 2018 --> Aug 2019
- | NN1213 / Novo Nordisk
Trial completion: Clinical Validation of Lophius Biosciences Kit T-Track (clinicaltrials.gov) - Aug 8, 2018
P=N/A, N=175, Completed, Sponsor: Lophius Biosciences GmbH
Recruiting --> Suspended | Trial primary completion date: Apr 2018 --> Aug 2019 Active, not recruiting --> Completed
- Trial completion, Trial completion date, Virus specific T cells: Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) (clinicaltrials.gov) - Apr 6, 2018
P1, N=10, Completed, Sponsor: ViraCyte
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2018
- ||| HB-101 / Hookipa Pharma
Trial completion, Trial completion date, Trial primary completion date: Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (clinicaltrials.gov) - Apr 3, 2018
P1, N=54, Completed, Sponsor: Hookipa Biotech
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> May 2017
- || Enrollment closed, Trial completion date, Trial primary completion date: Clinical Validation of Lophius Biosciences Kit T-Track (clinicaltrials.gov) - Mar 9, 2018
P=N/A, N=150, Active, not recruiting, Sponsor: Lophius Biosciences GmbH
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> Apr 2018 | Trial primary completion date: Sep 2017 --> Apr 2018
- Trial primary completion date, Virus specific T cells: Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) (clinicaltrials.gov) - Feb 20, 2018
P1, N=10, Active, not recruiting, Sponsor: ViraCyte
Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> Apr 2018 | Trial primary completion date: Sep 2017 --> Apr 2018 Trial primary completion date: Mar 2018 --> May 2017
- ||| Enrollment change: CMV-ACE/ASPECT: Alternate Donor Study of Pre-Emptive Cellular Therapy (clinicaltrials.gov) - Jan 25, 2018
P2, N=52, Completed, Sponsor: Cell Medica Ltd
Trial primary completion date: Mar 2018 --> May 2017 N=36 --> 52
- Enrollment closed, Trial primary completion date, Virus specific T cells: Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) (clinicaltrials.gov) - Jan 24, 2018
P1, N=10, Active, not recruiting, Sponsor: ViraCyte
N=36 --> 52 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Mar 2018
- ||| Enrollment closed, Trial primary completion date, IO biomarker, Post-transplantation: EVERCMV: Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (clinicaltrials.gov) - Jan 23, 2018
P4, N=186, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Mar 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2018
- | Enrollment closed: Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant (clinicaltrials.gov) - Jan 5, 2018
P4, N=160, Active, not recruiting, Sponsor: ORIOL BESTARD
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2018 Recruiting --> Active, not recruiting
- | filociclovir (MBX400) / Microbiotix
Trial completion: Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (clinicaltrials.gov) - Dec 26, 2017
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Terminated --> Completed
- | Trial primary completion date: Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant (clinicaltrials.gov) - Nov 1, 2017
P4, N=160, Recruiting, Sponsor: ORIOL BESTARD
Terminated --> Completed Trial primary completion date: Feb 2017 --> Jul 2018
- | Trial primary completion date: Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=60, Recruiting, Sponsor: University of Nebraska
Trial primary completion date: Feb 2017 --> Jul 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion: Q-CMV: Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients (clinicaltrials.gov) - Sep 21, 2017
P=N/A, N=32, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Mar 2017 --> Mar 2018 Active, not recruiting --> Completed
- | Triplex (CMV-MVA vaccine) / Fortress
Trial completion, Enrollment change, Triplex vaccine: Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus (clinicaltrials.gov) - Aug 2, 2017
P1, N=24, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 24
- | filociclovir (MBX400) / Microbiotix
Enrollment change: Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (clinicaltrials.gov) - Jul 21, 2017
P1, N=24, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=30 --> 24 N=32 --> 24
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Trial completion: Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients (clinicaltrials.gov) - Jun 30, 2017
P4, N=12, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=32 --> 24 Active, not recruiting --> Completed
- | Enrollment change, Trial termination, Trial primary completion date: Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT (clinicaltrials.gov) - Jun 4, 2017
P1, N=5, Terminated, Sponsor: Nelson Chao
Active, not recruiting --> Completed N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Feb 2015
- | Trial primary completion date: CMV: Screening for Congenital Cytomegalovirus Infection in Newborns (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=75, Enrolling by invitation, Sponsor: Southern Illinois University
N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Feb 2015 Trial primary completion date: Feb 2017 --> Feb 2018
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion, Trial primary completion date: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=32, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2015
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Q-CMV: Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=32, Active, not recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2015 Recruiting --> Active, not recruiting | N=50 --> 32 | Trial primary completion date: Dec 2015 --> Sep 2016
- || Trial primary completion date: Clinical Validation of Lophius Biosciences Kit T-Track (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=150, Recruiting, Sponsor: Lophius Biosciences GmbH
Recruiting --> Active, not recruiting | N=50 --> 32 | Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Jan 2017 --> Sep 2017
- | filociclovir (MBX400) / Microbiotix
Trial termination, Trial primary completion date: Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (clinicaltrials.gov) - Feb 27, 2017
P1, N=32, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jan 2017 --> Sep 2017 Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2017
- | Enrollment open, IO biomarker, Gene therapy: CMV_TCR-001: Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT (clinicaltrials.gov) - Feb 23, 2017
P1, N=10, Recruiting, Sponsor: University College, London
Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2017 Suspended --> Recruiting
- || HB-101 / Hookipa Pharma
Enrollment closed: Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (clinicaltrials.gov) - Jan 26, 2017
P1, N=54, Active, not recruiting, Sponsor: Hookipa Biotech
Suspended --> Recruiting Recruiting --> Active, not recruiting
- adimlecleucel (ATA230) / Atara
New trial, Virus specific T cells: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease (clinicaltrials.gov) - Jan 5, 2017
P=N/A, N=0, Temporarily Not Available, Sponsor: Atara Biotherapeutics
- New P1 trial, IO biomarker, Gene therapy: CMV_TCR-001: Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT (clinicaltrials.gov) - Dec 13, 2016
P1, N=10, Suspended, Sponsor: University College, London
- Enrollment open, IO biomarker, Virus specific T cells: VISIT: Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=30, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Enrollment closed, Trial primary completion date, Diagnostic assay: T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=600, Active, not recruiting, Sponsor: Oxford Immunotec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2017
- Enrollment open: Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=60, Recruiting, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- ||| Trial completion: REIVI: Cytomegalovirus-Specific Response Measured by QuantiFeron (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=92, Completed, Sponsor: Fundacio Catalana de Pneumologia
Not yet recruiting --> Recruiting Recruiting --> Completed
- Triplex (CMV-MVA vaccine) / Fortress
Trial primary completion date, Triplex vaccine: Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus (clinicaltrials.gov) - Aug 23, 2016
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed Trial primary completion date: Oct 2016 --> Oct 2017
- Trial completion, Enrollment change: Cytomegalovirus (CMV) Infection in Pregnancy (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=283, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed | N=220 --> 283
- Trial completion, Enrollment change: Cytomegalovirus (CMV) Infection in Amniotic Fluid (clinicaltrials.gov) - Aug 17, 2016
P=N/A, N=37, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | N=220 --> 283 Not yet recruiting --> Completed | N=300 --> 37
- Biomarker, New trial: CMV-R (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=1, Terminated, Sponsor: AdministrateurDRC
- Trial completion, Trial primary completion date: The Epidemiologic Study of Human Cytomegalovirus?CMV? in Female Students of Xiamen University (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=102, Completed, Sponsor: Jun Zhang
Not yet recruiting --> Completed | N=300 --> 37 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016
- HB-101 / Hookipa Pharma
Enrollment open: Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (clinicaltrials.gov) - Jul 13, 2016
P1, N=54, Recruiting, Sponsor: Hookipa Biotech
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- HB-101 / Hookipa Pharma
New P1 trial: Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (clinicaltrials.gov) - Jun 15, 2016
P1, N=54, Not yet recruiting, Sponsor: Hookipa Biotech
- CyMVectin (VCL-6365) / Fresh Tracks Therap
Enrollment change, Trial withdrawal: Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine (clinicaltrials.gov) - May 19, 2016
P1, N=0, Withdrawn, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting N=10 --> 0 | Not yet recruiting --> Withdrawn
- New trial: A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=1000, Completed, Sponsor: The Center for the Biology of Chronic Disease
- Trial primary completion date: Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT (clinicaltrials.gov) - Mar 18, 2016
P1, N=20, Recruiting, Sponsor: Nelson Chao
N=10 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Feb 2016 --> Feb 2017
- New trial: A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=1500, Recruiting, Sponsor: Jun Zhang
- | Cytovene (ganciclovir) / Roche, Vistide (cidofovir) / Gilead
Trial completion: Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) (clinicaltrials.gov) - Mar 12, 2016
P3, N=61, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Trial primary completion date: Feb 2016 --> Feb 2017 No longer recruiting --> Completed